Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Cassaday RD, Zarling LC, Garcia KA, Sala-Torra O, et al. Leuk Lymphoma 2023 Mar 20:1-11. doi: 10.1080/10428194.2023.2189803.

Read + Share

Amedeo Smart

Independent Medical Education

Cassaday RD, Zarling LC, Garcia KA, Sala-Torra O, et al. Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Leuk Lymphoma 2023 Mar 20:1-11. doi: 10.1080/10428194.2023.2189803.
PMID: 36938892